Personalis, ABRCC, and Criterium Announce Major Prospective Clinical Trial for Residual and Recurrent Disease Detection in Triple Negative Breast Cancer
FREMONT, Calif.--(BUSINESS WIRE)--Personalis, ABRCC, and Criterium announce major prospective clinical trial
